Company intelligence / Profile preview

Shanghai Brighten Optix Vision Technology

Ownership: Private
Development stage: Commercial

Overview

Brighten Optix is a global medical company specializing in custom gas permeable and silicone hydrogel contact lenses. Its products—including advanced orthokeratology and specialty lenses—are widely used for myopia management and general vision correction across Greater China and Southeast Asia. The company is recognized for its innovative R&D portfolio, with clinically proven solutions for slowing progressive myopia in children.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Assistive Medical Devices

Partnerships

Pending integration with Carl Zeiss following acquisition closure.

Beyond the preview

Go deeper on Shanghai Brighten Optix Vision Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Brighten Optix Vision Technology.

Explore the full profile